Literature DB >> 26751697

Pancreatic Kininogenase Ameliorates Renal Fibrosis in Streptozotocin Induced-Diabetic Nephropathy Rat.

Dan Zhu1, Linlin Zhang, Lijuan Cheng, Liansheng Ren, Jie Tang, Dianjun Sun.   

Abstract

BACKGROUND/AIMS: We aimed to evaluate whether pancreatic kininogenase (PKase) can relieve renal fibrosis and investigate its mechanisms in diabetic nephropathy (DN) rats
Methods: We established streptozotocin (STZ) induced-DN rats. After treatment with PKase for 4 weeks, urinary weight, urinary protein content and blood glucose concentration were detected, and then renal histopathological changes were examined using Hematoxylin and Eosin (H&E) and Masson's thrchrome staining. In addition, the expressions of miR-433, transforming growth factor-β1 (TGF-β1) and antizyme inhibitor 1 (Azin1) were detected by qRT-PCR and/or western blotting.
RESULTS: PKase reduced urinary weight, urinary protein contents and blood glucose concentrations. PKase treated DN rats exhibited less renal fibrosis than untreated DN rats (P < 0.05). Furthermore, the expression levels of TGF-β and miR-433 were reduced (P < 0.05), while Azin1 expression was increased in renal tissues of PKase treated DN rats compared with untreated DN rats (P < 0.05).
CONCLUSIONS: PKase might not only inhibit the development of DN by reducing urinary weight, urinary protein content and blood glucose concentration in DN rats, but also relieve renal fibrosis in DN rats through inhibiting the expression of TGF-β1, and miR-433 and Azin1 might involve in this process.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26751697     DOI: 10.1159/000368542

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  7 in total

1.  Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.

Authors:  María José Acuña; Daniela Salas; Adriana Córdova-Casanova; Meilyn Cruz-Soca; Carlos Céspedes; Carlos P Vio; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2017-12-17       Impact factor: 5.782

2.  Exogenous pancreatic kininogenase protects against renal fibrosis in rat model of unilateral ureteral obstruction.

Authors:  Ji-Zhe Jin; Hui-Ying Li; Jian Jin; Shang-Guo Piao; Xiong-Hu Shen; Yan-Ling Wu; Jia-Chong Xu; Long-Ye Zhang; Yu-Ji Jiang; Hai-Lan Zheng; Ying-Shun Jin; Sheng Cui; Kang Luo; Yi Quan; Can Li
Journal:  Acta Pharmacol Sin       Date:  2020-04-16       Impact factor: 6.150

3.  miR‑433 protects pancreatic β cell growth in high‑glucose conditions.

Authors:  Min Wang
Journal:  Mol Med Rep       Date:  2017-07-05       Impact factor: 2.952

4.  Pancreatic kininogenase improves erectile function in streptozotocin-induced type 2 diabetic rats with erectile dysfunction.

Authors:  Guo-Tao Chen; Bai-Bing Yang; Jian-Huai Chen; Zheng Zhang; Lei-Lei Zhu; He-Song Jiang; Wen Yu; Yun Chen; Yu-Tian Dai
Journal:  Asian J Androl       Date:  2018 Sep-Oct       Impact factor: 3.285

5.  Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.

Authors:  Ying Cheng; Xiaochen Yu; Jie Zhang; Yunpeng Chang; Mei Xue; Xiaoyu Li; Yunhong Lu; Ting Li; Ziyu Meng; Long Su; Bei Sun; Liming Chen
Journal:  Diabetologia       Date:  2019-03-05       Impact factor: 10.122

6.  Effects of L-carnitine combined with pancreatic kininogenase on thioredoxin 2, thioredoxin reductase 1, and sperm quality in patients with oligoasthenospermia.

Authors:  Yang Wang; Rui Zhang; Weijun Pan; Zhe Xu; Huan Yang; Qi Luo; Xiping Ye; Xianfeng Cheng
Journal:  Transl Androl Urol       Date:  2021-08

7.  Nephroprotective role of nanoencapsulated Tinospora cordifolia (Willd.) using polylactic acid nanoparticles in streptozotocin-induced diabetic nephropathy rats.

Authors:  Ragavee Ambalavanan; Arul Daniel John; Asha Devi Selvaraj
Journal:  IET Nanobiotechnol       Date:  2021-03-15       Impact factor: 2.050

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.